Immupharma PLC IMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
December 02 2020 - 1:00AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
02 December 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASE(TM) DIGITAL 2021
11-15 January 2021
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and
development company, announces that Dr Tim Franklin, ImmuPharma's
Chief Operating Officer, will be presenting at the prestigious
Biotech Showcase(TM) Digital 2021. The event will be virtually held
between 11 and 15 January 2021.
As part of ImmuPharma's participation, an on-demand Company
presentation has been provided in advance to the opening of the
event. This will allow registered attendees to get access to
presentation material prior to the start of the showcase on 11
January 2021.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an
investor conference focused on driving advances in therapeutic
development by providing a sophisticated networking platform for
executives and investors that fosters investment and partnership
opportunities. The conference takes place each year during the
course of one of the industry's largest gatherings and busiest
weeks.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker) +44 (0) 203 36 8 3550
Patrick Claridge
John Howes
Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, anti-infectives,
metabolic diseases and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase III for
the treatment of systemic lupus erythematosus (lupus / SLE). Lupus
is an autoimmune disease which if left untreated can be fatal.
Preclinical analysis suggest therapeutic activity for many other
autoimmune diseases that share the same autophagy mechanism of
action. ImmuPharma and Avion Pharmaceuticals signed on 28 November
2019, an exclusive licence and development agreement and trademark
agreement for Lupuzor(TM) to fund a new international Phase III
trial for Lupuzor(TM) and commercialise in the US.
For additional information about ImmuPharma please visit
www.immupharma.com .
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
About Biotech Showcase
Biotech Showcase is an investor and networking conference
devoted to providing private and public biotechnology and life
sciences companies with an opportunity to present to, and meet
with, investors and pharmaceutical executives in one place.
Investors and biopharmaceutical executives from around the world
gather in San Francisco during this bellwether week which sets the
tone for the coming year. Now in its 13th year, this
well-established, highly respected conference features multiple
tracks of presenting companies, plenary sessions, workshops,
networking, and an opportunity to schedule one-to-one meetings.
Biotech Showcase is produced by Demy-Colton and EBD Group. Both
organizations have a long history of producing high-quality
programs that support the biotechnology and broader life sciences
industry.
About Reach announcements
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
media only / non-regulatory news releases such as marketing
messages, corporate and product information into the public domain.
An RNS Regulatory announcement is required to be notified under the
AIM Rules for Companies.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUASORRKUURAA
(END) Dow Jones Newswires
December 02, 2020 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024